FIBRONEER-ILD Study To Improve Lung Function


Trial Objective

Continuous scarring (fibrosis) can gradually impair lung function, leading to breathing difficulties. Researchers are examining whether an investigational medication called BI 1015550 can help adults aged 18 and older with progressive lung diseases with fibrosis.

Participants in this study will be given BI 1015550 or a placebo (a tablet without any medication). All participants receive lung function tests, and the test results for both groups will be compared. Researchers will review the data to see if BI 1015550 improves lung function and may be another important tool in the fight against lung disease.


Active Clinical Trials Currently Recruiting

Who Can Participate

Adults 18 and older with progressive interstitial lung disease with fibrosis.  

Age: 18+    Gender: Any Gender

Estimated Time Commitment

10 clinic visits over 52 weeks, then visits every three months until all patients reach 52 weeks of treatment.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kaitlin Fier

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Boehringer Ingelheim

Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.

 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: